Kuros Biosciences AG, a leader in biologic technologies, is expanding its global footprint with a focus on its innovative MagnetOs product. During its Capital Markets Day, the company outlined its strategy to broaden market access, targeting both spinal and extremity markets across the U.S., Europe, and other regions. This expansion is supported by a strategic alliance with Medtronic, aimed at accelerating product adoption. Kuros is also investing in science, with seven Level I human clinical trials underway to demonstrate MagnetOs' efficacy in promoting bone growth and fusion. The company's efforts are geared towards improving patient outcomes while driving shareholder value through continued innovation and strategic growth.